



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/648,557	08/25/2000	Christian Devaux	1017753-000152	5736

21839 7590 06/08/2010  
BUCHANAN, INGERSOLL & ROONEY PC  
POST OFFICE BOX 1404  
ALEXANDRIA, VA 22313-1404

EXAMINER
----------

PARKIN, JEFFREY S

ART UNIT	PAPER NUMBER
----------	--------------

1648

NOTIFICATION DATE	DELIVERY MODE
-------------------	---------------

06/08/2010

ELECTRONIC

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

ADIPFDD@bipc.com  
offserv@bipc.com

Receipt date: 12/28/2006

09648557 - 1648

Attorney's Docket No. 1017753-000152



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of )

Christian DEVEAUX et al. )

Application No.: 09/648,557 )

Filed: August 25, 2000 )

For: INHIBITORS OF HIV REPLICATION )  
AND METHOD OF TREATMENT OF )  
HIV INFECTIONS )

Group Art Unit: 1648

Examiner: J. PARKIN

Confirmation No.: 5736

SECOND INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

The documents are being submitted after a first Office Action on the merits but prior to the closing of prosecution, therefore under 37 C.F.R. § 1.97(c), the fee set forth in 37 C.F.R. § 1.17(p) is enclosed.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.


The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY PC

Date: December 28, 2006

By:

  
Deborah H. Yellin  
Registration No. 45,904

P.O. Box 1404  
Alexandria, VA 22313-1404  
703 836 6620

12/29/2006 SZEWDIE1 00000070 09648557

01 FC:1606

160.00 0P

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.P./

Receipt date: 12/28/2006

DEC 28 2006

09648557 - GAU: 1648

Substitute for form 1449/PTO &amp; 1449B/PTO

Complete if Known

**SECOND  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	09/648,557
Filing Date	August 25, 2000
First Named Inventor	Christian DEVEAUX et al.
Examiner Name	J. PARKIN
Attorney Docket No.	1017753-000152

Sheet 1 of 1

**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	STATUS						
					Translation	Partial Translation	Eng. Lang. Summary	Search Report	IPER	Abstract	Cited in Spec
	WO 01/24810		WIPO	04/12/2001	X						
	WO 02/10201		WIPO	02/07/2002	X						

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	VAN DER BURG et al., "HIV-1 Reverse Transcriptase-Specific CTL Against Conserved Epitopes Do Not Protect Against Progression to AIDS", The Journal of Immunology, 1997, 159: pgs. 3648-3654.

Examiner Signature	/Jeffrey Parkin/	Date Considered	05/30/2010
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.P./